Cargando…
Luteolin is a potential inhibitor of COVID-19: An in silico analysis
The severe respiratory syndrome 2019 novel coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread explosively, raising global health concerns. Luteolin shows antiviral properties, but its effect on SARS-CoV-2 and the associated mechanisms...
Autores principales: | Wang, Wenxiang, Yang, Ce, Xia, Jing, Li, Ning, Xiong, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519465/ https://www.ncbi.nlm.nih.gov/pubmed/37746970 http://dx.doi.org/10.1097/MD.0000000000035029 |
Ejemplares similares
-
First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients
por: Chen, Hongyi, et al.
Publicado: (2020) -
Comorbidities’ potential impacts on severe and non-severe patients with COVID-19: A systematic review and meta-analysis
por: Cheng, Sixiang, et al.
Publicado: (2021) -
The relationship between hyperglycemia and the infection of COVID-19 in diabetic patients: A protocol for systematic review and meta-analysis
por: Liu, Yan, et al.
Publicado: (2020) -
Effectiveness of tocilizumab in the treatment of hospitalized adults COVID-19: A systematic review and meta-analysis
por: Zhang, Jing, et al.
Publicado: (2022) -
The clinical course and prognostic factors of severe COVID-19 in Wuhan, China: A retrospective case-control study
por: Liu, Jiacheng, et al.
Publicado: (2021)